No Data
Huadong Medicine has obtained approvals for three new products at the start of the year, which is nearly half of last year's total.|Quick read announcement.
1. Huadong Medicine announced today that three products have received approval for market entry, while a total of seven products were approved last year; 2. Among them, a hyaluronic acid product for medical aesthetics and a chemical drug for the treatment of ovarian cancer received domestic approval, while a medical instrument for assessing kidney function received approval in the USA; 3. Huadong Medicine believes that the approvals will not have a significant impact on the company's current financial situation and operational results.
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Huadong Medicine (000963.SZ): The clinical trial application for the HDM2006 pharmaceutical has received approval from the USA FDA.
On January 13th, Glorunhui reported that Huadong Medicine (000963.SZ) announced that on January 10, 2025, its wholly-owned subsidiary Hangzhou Sino-American Huadong Pharmaceutical Co., Ltd. received notification from the USA Food and Drug Administration. The clinical trial application for the HDM2006 tablet, submitted by Sino-American Huadong, has been approved by the USA FDA to conduct Phase I clinical trials for the indication of advanced malignant tumors. The HDM2006 tablet is independently developed by Sino-American Huadong targeting HPK1 (Hematopoietic Progenitor Kinase-1).
Sinolink: The market's attention to the left reversal of the pharmaceutical sector is increasing, with a focus on the related Sector of respiratory infections.
The proportion of influenza and other respiratory infections continues to rise, and it is recommended to closely monitor the infectious disease situation.
Sinolink: Major policies have been released, innovation remains the most important direction. The pharmaceutical and healthcare Industry has entered a performance window, focusing on reversal expectations.
The market has entered the window period for annual and quarterly reports, and it is recommended to actively pay attention to the fundamental Bearish clearance of left-side symbols (such as some Medical Devices, Traditional Chinese Medicine, pharmacies, chain Medical, CXO, etc.) and the implementation of centralized procurement policies.
Huadong Medicine Subsidiary Gets Aproval for HDM1005 Weight Management Drug Clinical Trials
Fewer Investors Than Expected Jumping On Huadong Medicine Co., Ltd (SZSE:000963)
No Data
